Jan 6 2010
CyDex Pharmaceuticals Inc., a specialty pharmaceutical company, today
announced that the U.S. Patent and Trademark Office (USPTO) has issued a
patent to CyDex entitled “Sulfoalkyl Ether Cyclodextrin Compositions.”
This patent, along with other previously issued technology patents, will
provide broad protection for CyDex’s Captisol® technology
until 2029. The most recent of these previously issued patents – for a
new Captisol that flows better, dissolves faster, and packs more densely
than previous morphologies – was announced on December 9, 2009.
“Receiving this new patent is an important achievement as we continue to
license Captisol technology and develop our own products that target
unmet needs in hospital intravenous therapy”
The patent announced today (U.S. Patent No. 7,635,773) covers a
manufacturing process for producing ultra high-purity modified
cyclodextrins, and specifically the beta cyclodextrin sulfobutyl ether
sodium salt product known as Captisol. Captisol is CyDex’s proven
enabling drug delivery technology that aids in the solubilization,
stabilization and taste masking of active pharmaceutical ingredients.
“Receiving this new patent is an important achievement as we continue to
license Captisol technology and develop our own products that target
unmet needs in hospital intravenous therapy,” said Dr. Theron Odlaug,
President and Chief Executive Officer of CyDex Pharmaceuticals.
“High-purity Captisol removes many impurities and degradants so that the
composition can be used to increase the stability of highly sensitive
active pharmaceutical ingredients. Together with the morphology patent
we received earlier this month, this patent ultimately provides broader
protection for our clients using Captisol and provides them with
critical life-cycle management for their products.”
Captisol is manufactured using a validated, patent-protected process and
conforms to USP <1078> on Good Manufacturing Practices for Bulk
Pharmaceutical Excipients.
http://www.cydexpharma.com/